S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The Safest Option in Trades! (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
The Safest Option in Trades! (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
The Safest Option in Trades! (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The Safest Option in Trades! (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
The Safest Option in Trades! (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
The Safest Option in Trades! (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The Safest Option in Trades! (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
The Safest Option in Trades! (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
The Safest Option in Trades! (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The Safest Option in Trades! (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
The Safest Option in Trades! (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
The Safest Option in Trades! (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
OTCMKTS:BVNRY

Bavarian Nordic A/S - BVNRY Stock Forecast, Price & News

$11.31
+0.21 (+1.89%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$11.22
$11.37
50-Day Range
$9.15
$12.23
52-Week Range
$5.85
$19.31
Volume
26,218 shs
Average Volume
131,675 shs
Market Capitalization
$2.40 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BVNRY stock logo

About Bavarian Nordic A/S (OTCMKTS:BVNRY) Stock

Bavarian Nordic A/S is a fully-integrated biotechnology company focused on vaccination technology. The company’s work is built around two primary platforms that provide numerous benefits to the health industry and individuals. The company’s primary technology is MVA-BN which stands for Modified Vaccine Ankara-Bavarian Nordic. This vaccination platform is a non-replicating platform, meaning that live-virus vaccines cannot reproduce and spread within the host. This is central to the platform's high tolerance rate. MVA-BN is approved as a smallpox and monkeypox vaccine in the US, Canada, and the EU. It is also included in the US Strategic National Stockpile and is being used worldwide to control the 2022 Monkeypox outbreak.

Bavarian Nordic is headquartered in Hellerup, Denmark with manufacturing sites in Denmark and Germany. The company maintains offices in Switzerland, the UK, Japan, and North Carolina in the United States. The company was incorporated in 1992 and had 4 approved products under 7 brand names available for use. Its MVA-BN non-replicating smallpox and monkeypox vaccines are available under the IMVAMUNE, IMVANEX and JYNNEOS names.

The company’s second platform is the Vaccinia-Fowlpox-TRICOM platform for treating cancers. The platform can be targeted to attack specific markers found in numerous cancers. The company’s other marketable vaccines are Rabipur for rabies, MVABEA for Ebola and Marburg Hemorrhagic fever, and Encepur for tick-borne encephalitis.

The company’s pipeline has 4 potential candidates for the market. These include a freeze-dried version of MVA-BN for smallpox, MVA-BN for RSV (respiratory infection), and TAEK-VAC for certain cancers. The company’s COVID-19/SARS vaccine boosters have shown effectiveness 6 months after dosing. 

Receive BVNRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bavarian Nordic A/S and its competitors with MarketBeat's FREE daily newsletter.

BVNRY Stock News Headlines

Bavarian Nordic boosted by monkeypox vaccine
Monkeypox Outbreak Leaves Risks, Questions in Its Wake
Bavarian Nordic A/S
Bavarian Nordic A/S Could Post A Strong Comeback
See More Headlines
Receive BVNRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bavarian Nordic A/S and its competitors with MarketBeat's FREE daily newsletter.

BVNRY Company Calendar

Today
12/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:BVNRY
CIK
N/A
Employees
759
Year Founded
N/A

Profitability

Net Income
$-73,950,000.00
Pretax Margin
-35.01%

Debt

Sales & Book Value

Annual Sales
$301.90 million
Book Value
$5.55 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.40 billion
Optionable
Not Optionable
Beta
1.56

Key Executives

  • Dr. Paul John Chaplin MSc (Age 55)
    Ph.D., CEO & Pres
    Comp: $1.29M
  • Mr. Henrik Juuel M.Sc. (Age 57)
    CFO & Exec. VP
    Comp: $677.77k
  • Mr. Russell Thirsk
    Exec. VP & COO
  • Mr. Rolf Sass Sørensen
    VP of Investor Relations & Communications
  • Ms. Anu Helena Kerns (Age 50)
    Exec. VP & Chief People Officer
  • Mr. Jean-Christophe May (Age 55)
    Exec. VP & Chief Commercial Officer
  • Dr. Laurence De Moerlooze (Age 58)
    Exec. VP & Chief Medical Officer













BVNRY Stock - Frequently Asked Questions

Should I buy or sell Bavarian Nordic A/S stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bavarian Nordic A/S in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BVNRY shares.
View BVNRY analyst ratings
or view top-rated stocks.

How have BVNRY shares performed in 2022?

Bavarian Nordic A/S's stock was trading at $13.45 at the beginning of 2022. Since then, BVNRY shares have decreased by 15.9% and is now trading at $11.31.
View the best growth stocks for 2022 here
.

Are investors shorting Bavarian Nordic A/S?

Bavarian Nordic A/S saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 4,700 shares, an increase of 23.7% from the October 15th total of 3,800 shares. Based on an average daily trading volume, of 66,400 shares, the days-to-cover ratio is presently 0.1 days.
View Bavarian Nordic A/S's Short Interest
.

What is Bavarian Nordic A/S's stock symbol?

Bavarian Nordic A/S trades on the OTCMKTS under the ticker symbol "BVNRY."

How do I buy shares of Bavarian Nordic A/S?

Shares of BVNRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bavarian Nordic A/S's stock price today?

One share of BVNRY stock can currently be purchased for approximately $11.31.

How much money does Bavarian Nordic A/S make?

Bavarian Nordic A/S (OTCMKTS:BVNRY) has a market capitalization of $2.40 billion and generates $301.90 million in revenue each year.

How many employees does Bavarian Nordic A/S have?

The company employs 759 workers across the globe.

How can I contact Bavarian Nordic A/S?

Bavarian Nordic A/S's mailing address is Hejreskovvej 10A, Kvistgaard G7, 3490. The official website for the company is www.bavarian-nordic.com. The company can be reached via phone at (453) 326-8383, via email at investor@bavarian-nordic.com, or via fax at 45-3326-8380.

This page (OTCMKTS:BVNRY) was last updated on 12/2/2022 by MarketBeat.com Staff